A randomized, double-blind, placebo-controlled phase II trial to explore the effects of a GABAA-α5 NAM (basmisanil) on intellectual disability associated with Down syndrome

  1. Goeldner, C.
  2. Kishnani, P.S.
  3. Skotko, B.G.
  4. Casero, J.L.
  5. Hipp, J.F.
  6. Derks, M.
  7. Hernandez, M.-C.
  8. Khwaja, O.
  9. Lennon-Chrimes, S.
  10. Noeldeke, J.
  11. Pellicer, S.
  12. Squassante, L.
  13. Visootsak, J.
  14. Wandel, C.
  15. Fontoura, P.
  16. d’Ardhuy, X.L.
  17. De La Torre Fornell, R.
  18. Glue, P.
  19. Hoover-Fong, J.
  20. Uhlmann, S.
  21. Malagón Valdez, J.
  22. Marshall, A.
  23. Martinón-Torres, F.
  24. Redondo-Collazo, L.
  25. Rodriguez-Tenreiro, C.
  26. Marquez Chin, V.
  27. Michel Reynoso, A.G.
  28. Mitchell, E.A.
  29. Slykerman, R.F.
  30. Wouldes, T.
  31. Loveday, S.
  32. Moldenhauer, F.
  33. Novell, R.
  34. Ochoa, C.
  35. Rafii, M.S.
  36. Rebillat, A.-S.
  37. Sanlaville, D.
  38. Sarda, P.
  39. Shankar, R.
  40. Pulsifer, M.
  41. Evans, C.L.
  42. Silva, A.M.
  43. McDonough, M.E.
  44. Stanley, M.
  45. McCary, L.M.
  46. Vicari, S.
  47. Wilcox, W.
  48. Zampino, G.
  49. Zuddas, A.
  50. Mostrar todos os autores +
Revista:
Journal of Neurodevelopmental Disorders

ISSN: 1866-1955,  1866-1947

Ano de publicación: 2022

Volume: 14

Número: 1

Tipo: Artigo

DOI: 10.1186/S11689-022-09418-0 GOOGLE SCHOLAR lock_openAcceso aberto editor
Fonte de datos: Scopus